March 2007 | Oncology & Biotech News

The Industry Insider: March 2007

August 17, 2010

Additional breaking news from the biotech industry. In this issue: 1) FDA OKs Ikonisys' Bladder Cancer Test 2) Good News From China for Peregrine 3) Introgen Sees Advances on Two Fronts 4) Debiopharm Procures Cancer Therapy from Kirin Brewery

The Academy: March 2007

August 17, 2010

The Academy delivers the latest news on biotech and oncology research, providing a link between the clinical world of cancer care and the university researchers who are pushing the envelope of knowledge and discovery.

Politics & Policy: March 2007

August 17, 2010

The Politics and Policy page provides a concise and timely round-up of key government-related oncology and biotechnology news. Content is focused upon the public sector activities that are most likely to impact the evolving oncology and biotech industries.

The A-Z Business Wire

August 16, 2010

The latest business and financial biotech news. In this issue: 1) Adherex Buys Back GSK%u2019s Rights to Failed Cancer Drug 2) Archemix and Merck Partner on Aptamer-Based Cancer Therapeutics, and more

The Virtual Window: Clinical Trial Reports--March 2007

August 16, 2010

Successful research into new therapies for cancer requires a ready supply of patients willing to participate in clinical trials, and physicians and other health care professionals who will refer their patients to the appropriate studies.

News Reports; March 2007

August 16, 2010

News items reported in this issue: 1) 186-Gene Signature in Cancer Stem Cells Predicts Recurrence 2) National Prostate Cancer Coalition Commences Clinical Trial Education Program 3) Concomitant High-Dose Radiation Therapy Plus Cetuximab Improves Locoregional Control and Reduces Mortality, with No Increase in Radiation Therapy%u2013Associated Toxicity in Patients with Advanced Squamous-Cell Carcinoma of the Head and Neck, and more

Welcome Back: A Dynamic and Innovative Field Deserves an Innovative Publication

August 16, 2010

The fields of oncology and biotechnology are entering a period of rapid growth and transformation. It is an exciting time for physicians, researchers, and allied healthcare professionals. We are honored to be apart of the process.